Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: Presentation and outcomes of adults at a single center

Background/Introduction.Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a chronic demyelinating disorder that has been increasingly recognized since the serum antibody became commercially available in 2017. The most common clinical presentation is optic neuritis, and first line acute treatment is intravenous (IV) steroids. However, there are many questions that remain unanswered. For clinicians and patients, the primary question is whether relapses will occur and whether to treat with chronic therapy.

Source: Journal of Neuroimmunology - October 14, 2022 Category: Allergy & Immunology Authors: Paige Sutton, Michael W. Lutz, F. Lee Hartsell, Dorlan Kimbrough, N. Troy Tagg, Mark Skeen, Nicholas M. Hudak, Christopher Eckstein, Suma Shah Source Type: research